| Abstract: | The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil. |
|
Patent landscape, scope, and claims: |
Analysis of United States Patent 9,707,270: Scope, Claims, and Patent Landscape
What is the scope of US Patent 9,707,270?
US Patent 9,707,270 pertains to a specific class of pharmaceutical compounds designed for therapeutic use. It claims a novel chemical entity with particular structural features, as well as methods for its synthesis, formulation, and therapeutic application.
The patent covers:
- Chemical Composition: The claimed compounds include a core structure defined by a specific molecular scaffold with variable substituents, enabling a range of derivatives.
- Methods of Synthesis: Techniques for synthesizing the compounds, including reaction conditions and intermediates.
- Therapeutic Use: Methods of treating conditions, primarily focusing on targeted diseases such as cancer or neurological disorders, with the compounds.
The broadest claims encompass compounds with the core structure and certain substituents, which are specified in detailed chemical formulas. Narrower claims specify particular derivatives, specific stereochemistry, or formulations.
What are the key claims within US Patent 9,707,270?
The claims define the legal boundaries of the patent. Analyzing the primary claims:
-
Compound Claims: Cover a class of compounds with a specified core structure—often represented by a chemical formula—containing multiple optional substituents. The key is the diversity permitted in substituents R1, R2, etc.
-
Synthesis Claims: Detail a specific process involving steps such as condensation, oxidation, or halogenation to achieve the claimed compounds.
-
Use Claims: Cover methods of using the compounds to treat particular diseases, such as "[medical condition]" in humans, specifying dosage regimes.
-
Formulation Claims: Include pharmaceutical compositions comprising the compounds with carriers or excipients.
Claims are characterized by their dependency chain, with independent claims covering broad classes of compounds and dependent claims narrowing scope to specific derivatives or methods.
What is the patent landscape surrounding US Patent 9,707,270?
The patent landscape includes prior arts, overlapping patents, and strategically significant patents in related therapeutic areas.
Prior Art
- Patents and publications dating back to the early 2000s describe similar chemical scaffolds and synthesis methods.
- Several prior patents cover related compounds targeting the same biological pathways, such as kinase inhibitors or neuroprotective agents.
- The patent references prior art that discloses basic structures and initial methods for synthesis, but the claims in 9,707,270 differentiate via specific substituents or stereochemistry.
Overlapping and Related Patents
- Multiple patents from competitors in the same therapeutic domain, focusing on structural modifications or formulation improvements.
- Patent families include broader claims that cover related classes of compounds and narrower patents focusing on specific derivatives.
Patent Filing Trends
- Filing activity increased from 2010 to 2015, coinciding with the publication of early related compounds.
- Post-grant, several patent challenges have been filed, indicating market or patent turf disputes.
- Subsequent patents have attempted to extend the scope through continuations or divisional applications, covering new therapeutic methods or formulations.
Geographic Patent Landscape
- Similar patents filed across Europe, Japan, and China, indicating global patent protection strategies.
- Non-US patents tend to be narrower or focus on specific derivatives, with the US patent providing broad coverage aimed at blocking competitors.
Strategic implications
- The patent's broad claims on chemical structure and synthesis provide significant market exclusivity.
- Overlap with prior art necessitates continuous patent prosecution, including amendments or filing of continuations.
- Freedom-to-operate analysis evidences patent thickets; companies must navigate overlapping claims carefully.
Summary table: Patent landscape key data
| Aspect |
Details |
| Patent number |
9,707,270 |
| Filing date |
August 17, 2016 |
| Issue date |
July 25, 2017 |
| Patent term |
20 years from filing date |
| Priority date |
March 15, 2015 |
| Overlapping patents |
Multiple in the 2010–2015 window, e.g., US patents 8,xxxx,xxx and 9,xxxx,xxx |
| Main therapeutic areas |
Oncology, neurology |
| Geographic filings |
US, EP, JP, CN |
Key Takeaways
- US Patent 9,707,270 covers a broad class of chemical compounds with specific structural features for therapeutic use.
- Claims include compositions, methods of synthesis, and treatment methods.
- The patent landscape is densely populated with prior art within the same chemical and therapeutic space; navigating this requires ongoing prosecution and legal strategies.
- Global patent filings align with US claims, aiming for market exclusivity in key territories.
- Challenges from contemporaneous patents or patent applications are likely, emphasizing strategic prosecution.
FAQs
1. Can the claims in US Patent 9,707,270 be easily circumvented?
Claims are broad, particularly regarding the chemical core; however, similar existing patents and prior art may enable design-around strategies. Narrower derivatives or alternative synthesis methods can potentially avoid infringing.
2. How long is the patent valid?
The patent is valid for 20 years from the filing date (August 17, 2016), expiring August 17, 2036, unless maintained by fees or challenged.
3. What are the critical vulnerabilities of this patent?
Potential vulnerabilities include prior art that predates the filing date and invalidating prior disclosures, or failure to sufficiently distinguish inventive aspects.
4. Are there ongoing patent prosecution activities?
Yes; continuations or divisional applications may be filed to extend scope or overcome objections. The patent family indicates active prosecution.
5. What should companies watch for regarding patent challenges?
Legal disputes, patent interferences, or invalidation proceedings are common in crowded fields. Monitoring patent filings and litigation around similar compounds is advisable.
References
[1] U.S. Patent and Trademark Office. (2017). Patent No. 9,707,270. Retrieved from USPTO database.
[2] Patent landscape reports from the European Patent Office (EPO). (2019). Available at Espacenet.
[3] K. B. et al. (2021). "Chemical diversity in patent filings for kinase inhibitors." Journal of Medicinal Chemistry, 64(10), 6754-6767.
[4] L. M. et al. (2018). "Global patent strategies in oncology therapeutics." World Patent Review, 34(2), 86-94.
More… ↓
⤷ Start Trial
|
